: Influenza can be a significant public health problem. Nevertheless, it is preventable through vaccination. Concerning the pediatric population, the recommendation of influenza vaccination is under-represented in many European countries. The aim of this systematic review is to evaluate the cost-effectiveness of universal childhood vaccination against influenza in Europe.: We conducted a systematic review of original article assessing the cost-effectiveness of influenza vaccination by searching PubMed, Embase and Scopus databases for studies in English, starting from January 1, 2010 up to October 21, 2020.: Our literature review showed that all studies identified highlight that pediatric vaccinations using a live vaccine, especially in the quadrivalent formulation, are cost-effective compared to current vaccinations (elderly and at-risk groups) with TIV or no vaccination. A significant contribution to this positive economic profile is due to the indirect protection. Already many clinical data report the relevant direct and indirect impact of vaccination against influenza for younger subjects. The recent studies collected in this review showed also that the pediatric vaccination is also cost-effective. Therefore, decision-makers should now consider this new favorable evidence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14737167.2021.1925110 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Avian influenza mRNA vaccine encoding hemagglutinin provides complete protection against divergent H5N1 viruses in specific-pathogen-free chickens.
J Nanobiotechnology
January 2025
College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, China.
Background: The rapid mutation of avian influenza virus (AIV) poses a significant threat to both the poultry industry and public health. Herein, we have successfully developed an mRNA-LNPs candidate vaccine for H5 subtype highly pathogenic avian influenza and evaluated its immunogenicity and protective efficacy.
Results: In experiments on BALB/c mice, the vaccine candidate elicited strong humoral and a certain cellular immune responses and protected mice from the heterologous AIV challenge.
Replication-incompetent VSV-based vaccine elicits protective responses against SARS-CoV-2 and influenza virus.
Sci Adv
January 2025
Department of Microbiology and Immunology, Cornell University College of Veterinary Medicine, Ithaca, NY 14853, USA.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses lead to severe respiratory illnesses and death in humans, exacerbated in individuals with underlying health conditions, remaining substantial global public health concerns. Here, we developed a bivalent replication-incompetent single-cycle pseudotyped vesicular stomatitis virus vaccine that incorporates both a prefusion-stabilized SARS-CoV-2 spike protein lacking a furin cleavage site and a full-length influenza A virus neuraminidase protein. Vaccination of K18-hACE2 or C57BL/6J mouse models generated durable levels of neutralizing antibodies, T cell responses, and protection from morbidity and mortality upon challenge with either virus.
View Article and Find Full Text PDFProgrammable Stapling Peptide Based on Sulfonium as Universal Vaccine Adjuvants for Multiple Types of Vaccines.
Adv Sci (Weinh)
January 2025
State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, P. R. China.
Adjuvants are non-specific immune enhancers commonly used to improve the responsiveness and persistence of the immune system toward antigens. However, due to the undefined chemical structure, toxicity, non-biodegradability, and lack of design technology in many existing adjuvants, it remains difficult to achieve substantive breakthroughs in the adjuvant research field. Here, a novel adjuvant development strategy based on stapling peptides is reported to overcome this challenge.
View Article and Find Full Text PDFIdentifying emerging drivers and interventions to reduce vaccine hesitancy among long-term care facility nursing staff.
Gerontologist
January 2025
Population Health Initiative, University of Washington, Seattle, WA, USA.
Background And Objectives: The study aimed to identify key drivers of vaccine hesitancy among healthcare workers (HCWs) employed at Long-term care facilities (LTCF) within selected states. It also sought to determine which interventions, policies, and programs effectively reduced HCW vaccine hesitancy for COVID-19 and influenza.
Research Design And Methods: The study employed a mixed methods approach, combining secondary analysis of the Behavioral Risk Factor Surveillance System (BRFSS) data, survey research, and focus groups.
Preferences of nurses in the United Kingdom for attributes of pediatric hexavalent vaccines: a discrete-choice experiment.
Expert Rev Pharmacoecon Outcomes Res
January 2025
Merck & Co. Inc, Rahway, NJ, USA.
Background: We evaluated UK nurses' preferences for pediatric hexavalent vaccine attributes.
Research Design And Methods: In a discrete-choice experiment study, 150 nurses chose between 2 hypothetical pediatric hexavalent vaccines with varying attribute levels (device type, plastic in packaging, time on the market, and time the vaccine can stay safely at room temperature) in a series of choice questions. Using random-parameters logit-model estimates, conditional relative attribute importance (CRAI) and odds ratios (ORs) were calculated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!